Jim Simons’s Actinium Pharmaceuticals ATNM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $373K | Sell |
380,491
-91,109
| -19% | -$105K | ﹤0.01% | 2712 |
|
|
2026
Q1 | $469K | Buy |
471,600
+80,816
| +21% | +$96.1K | ﹤0.01% | 2631 |
|
|
2025
Q4 | $531K | Buy |
390,784
+102,154
| +35% | +$149K | ﹤0.01% | 2551 |
|
|
2025
Q3 | $462K | Buy |
288,630
+79,129
| +38% | +$129K | ﹤0.01% | 2834 |
|
|
2025
Q2 | $293K | Buy |
209,501
+151,901
| +264% | +$227K | ﹤0.01% | 3047 |
|
|
2025
Q1 | $92.7K | Sell |
57,600
-132,800
| -70% | -$169K | ﹤0.01% | 3209 |
|
|
2024
Q4 | $240K | Buy |
190,400
+63,400
| +50% | +$98.4K | ﹤0.01% | 3114 |
|
|
2024
Q3 | $239K | Buy |
127,000
+107,800
| +561% | +$426K | ﹤0.01% | 3065 |
|
|
2024
Q2 | $142K | Buy |
+19,200
| New | +$158K | ﹤0.01% | 3115 |
|
|
2023
Q3 | – | Sell |
-48,302
| Closed | -$358K | – | 3645 |
|
|
2023
Q2 | $358K | Sell |
48,302
-53,898
| -53% | -$459K | ﹤0.01% | 3048 |
|
|
2023
Q1 | $966K | Sell |
102,200
-57,400
| -36% | -$606K | ﹤0.01% | 2500 |
|
|
2022
Q4 | $1.7M | Buy |
159,600
+81,300
| +104% | +$825K | ﹤0.01% | 2179 |
|
|
2022
Q3 | $578K | Buy |
78,300
+20,600
| +36% | +$128K | ﹤0.01% | 2845 |
|
|
2022
Q2 | $278K | Buy |
+57,700
| New | +$328K | ﹤0.01% | 3500 |
|
|
2020
Q3 | – | Sell |
-120,212
| Closed | -$1.27M | – | 3363 |
|
|
2020
Q2 | $1.27M | Buy |
120,212
+80,664
| +204% | +$611K | ﹤0.01% | 2429 |
|
|
2020
Q1 | $230K | Buy |
39,548
+6,537
| +20% | +$46.4K | ﹤0.01% | 3066 |
|
|
2019
Q4 | $216K | Buy |
33,011
+16,325
| +98% | +$113K | ﹤0.01% | 3175 |
|
|
2019
Q3 | $115K | Buy |
16,686
+9,632
| +137% | +$67K | ﹤0.01% | 3249 |
|
|
2019
Q2 | $52K | Buy |
7,054
+2,409
| +52% | +$24.2K | ﹤0.01% | 3450 |
|
|
2019
Q1 | $67K | Buy |
4,645
+1,911
| +70% | +$30.5K | ﹤0.01% | 3342 |
|
|
2018
Q4 | $32K | Sell |
2,734
-11,385
| -81% | -$194K | ﹤0.01% | 3307 |
|
|
2018
Q3 | $314K | Buy |
14,119
+1,202
| +9% | +$24.5K | ﹤0.01% | 3003 |
|
|
2018
Q2 | $248K | Buy |
12,917
+11,974
| +1,270% | +$152K | ﹤0.01% | 3022 |
|
|
2018
Q1 | $10K | Buy |
+943
| New | +$16K | ﹤0.01% | 3336 |
|
|
2017
Q3 | – | Sell |
-382
| Closed | -$14K | – | 3195 |
|
|
2017
Q2 | $14K | Sell |
382
-2,729
| -88% | -$114K | ﹤0.01% | 3162 |
|
|
2017
Q1 | $141K | Sell |
3,111
-707
| -19% | -$27.1K | ﹤0.01% | 3040 |
|
|
2016
Q4 | $100K | Buy |
+3,818
| New | +$119K | ﹤0.01% | 3102 |
|
|
2015
Q2 | – | Sell |
-3,160
| Closed | -$234K | – | 3214 |
|
|
2015
Q1 | $234K | Buy |
+3,160
| New | +$376K | ﹤0.01% | 2833 |
|
Other funds holding ATNM
VCM
CFML
GS
VFT
GWP
Jim Simons's ATNM Position: Q2 2026 in Review
Jim Simons reduced its Actinium Pharmaceuticals (ATNM) stake by 19% in Q2 2026, selling an estimated $105K and leaving 380,491 shares worth $373K. The position accounts for ﹤0.01% of the portfolio, ranked #2712.
Jim Simons first reported a position in ATNM in Q1 2015 and has held it in 28 quarters since. The position peaked at $1.7M in Q4 2022. 36 funds tracked by Wall St. Rank hold ATNM as of Q2 2026.
- Jim Simons held 380,491 shares of Actinium Pharmaceuticals worth $373K as of Q2 2026.
- Jim Simons sold 91,109 Actinium Pharmaceuticals shares in Q2 2026, an estimated $105K.
- Actinium Pharmaceuticals made up ﹤0.01% of Jim Simons's portfolio in Q2 2026, its #2712 holding.
- Jim Simons first reported a position in Actinium Pharmaceuticals in Q1 2015 and has held it in 28 quarters since.
- Jim Simons's Actinium Pharmaceuticals position peaked at $1.7M in Q4 2022.
- 36 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q2 2026.
Based on Renaissance Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.